Hansa Biopharma AB (OSTO:HNSA) Construction In Progress: kr0.0 Mil (As of Mar. 2026)


OSTO:HNSA Hansa Biopharma AB OSTO:HNSA
49 GF Score
Price kr34.40
GF Value kr24.55
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Construction In Progress?

Hansa Biopharma AB OSTO:HNSA +3.93% 49 Construction In Progress is kr0.0 Mil as of Mar. 2026. GuruFocus rates OSTO:HNSA with a GF Score™ of 49/100 and a GF Value™ of kr24.55 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Hansa Biopharma AB Construction In Progress Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB Construction In Progress Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hansa Biopharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:HNSA
49GF Score
Hansa Biopharma AB OSTO:HNSA
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of kr0.0 Mil mean?
Hansa Biopharma AB (OSTO:HNSA) has a Construction In Progress of kr0.0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Construction In Progress too high?
Hansa Biopharma AB's current Construction In Progress is kr0.0 Mil. Overall, Hansa Biopharma AB has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Construction In Progress compare to VRTX and REGN?
Hansa Biopharma AB's Construction In Progress of kr0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Construction In Progress is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.55, compared to a current price of kr34.40 — trading 40.1% above its estimated fair value. The current Construction In Progress is kr0.0 Mil. Hansa Biopharma AB's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current Construction In Progress is kr0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr34.40 is trading 40.1% above its estimated GF Value™ of kr24.55. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for OSTO:HNSA:

  • Construction In Progress: kr0.0 Mil
  • GF Value™: kr24.55 vs. price of kr34.40 (40.1% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score

Get the complete analysis for OSTO:HNSA

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr34.40
Price
kr24.55
GF Value